MCL Literature Feed

This review highlights BTK's non-catalytic scaffolding function as a novel mechanism of BTKi resistance, presenting a new therapeutic target beyond kinase inhibition for treating B-cell lymphomas like MCL.

BTK inhibition suppresses key metabolic pathways, allowing non-invasive imaging of metabolites like lactate and alanine as early, sensitive biomarkers of therapeutic response in MCL patients.

A computational, network-based analysis of MCL transcriptomic data identified novel progression pathways, highlighting VEGFA and SPARC as potential drug targets and providing a framework for drug repurposing.

This case report describes a novel nodular endoscopic presentation of primary nasopharyngeal MCL, expanding the differential diagnosis for nodular lesions in this rare location beyond benign or infectious causes.

This case report of an 80-year-old woman with laryngeal MCL highlights a rare extranodal presentation, underscoring the need to consider lymphoma in the differential for persistent throat symptoms.

CD20-targeted CAR-T therapy induced durable remissions (>7 years) in MCL by triggering a lasting endogenous anti-tumor immune response (epitope spreading) despite a lack of CAR-T persistence.

This paper likely provides a retrospective or real-world analysis of the incidence, types, and risk factors for infections in MCL, informing clinical decisions on prophylaxis and supportive care.

A computational virtual screen of over 2.4 million compounds identified novel covalent BTK inhibitors, providing a foundation for developing next-generation therapeutics for MCL.

This large US prospective cohort study suggests outdoor air pollution is a potential environmental risk factor for developing specific hematologic cancer subtypes, highlighting the importance of subtype-specific etiological research.

This case series on a rare kidney disease (ABBA) reports a paraneoplastic association with mantle cell lymphoma, highlighting a rare non-hematologic manifestation potentially responsive to B-cell directed therapy.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.

The dual HCK/BTK inhibitor KIN-8194 preclinically overcomes primary and acquired BTKi resistance in MCL by targeting HCK-mediated growth and adhesion, offering a novel therapeutic strategy.

The R-GEMOX (rituximab, gemcitabine, oxaliplatin) chemotherapy regimen demonstrates efficacy as a salvage option for patients with relapsed/refractory mantle cell lymphoma in a phase I/II study.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

This review synthesizes current knowledge on MCL genetic markers, advocating for a personalized medicine approach that integrates molecular profiles like TP53 to improve risk stratification and guide therapy.

This preclinical study identifies a novel cyclin D1 degradation pathway via SUMOylation, showing its disruption causes an MCL-like phenotype and that arsenic trioxide can therapeutically enhance this process.

A qualitative study of Japanese MCL patients reveals that convenience, quality of life, and shared decision-making are key treatment preferences, alongside efficacy and safety, guiding personalized care.

In a large real-world cohort, mantle cell lymphoma patients exhibited higher CAR19 expansion than other lymphomas, which directly correlated with increased toxicity and significantly higher steroid requirements.

Profiling T-cell differentiation stages in MCL reveals novel immunotherapeutic targets in specific patient subsets, suggesting a biomarker-driven approach for future immune-based treatments.

The CDK9 inhibitor enitociclib overcomes resistance to both BTK inhibitors and CAR-T therapy, offering a potential new strategy for double-refractory mantle cell lymphoma.

The SOX11/PRDX2 axis is identified as a key regulator of chemoresistance in aggressive MCL by controlling redox homeostasis, offering a potential new therapeutic target.

In a retrospective analysis of 95 MCL cases, specific histopathological patterns of bone marrow involvement were identified as key prognostic indicators, aiding in initial patient risk stratification.

This case series characterizes the immunohistochemical and molecular genetic profile of rare lacrimal gland MCL, providing crucial diagnostic insights for this uncommon extranodal presentation.

An 85-year-old MCL patient on ibrutinib developed a cutaneous EBV+ NK/T-cell lymphoma that resolved spontaneously, highlighting a rare, potentially indolent lymphoproliferative disorder in this treatment setting.

PRMT5 promotes MCL growth via MYC-driven lipid metabolism reprogramming, identifying it as a poor prognostic marker and a novel therapeutic target with preclinical inhibitor activity.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

A rare case of primary adrenal mantle cell lymphoma presenting as a retroperitoneal mass mimicking paraganglioma highlights the critical need for histological diagnosis of atypical adrenal tumors.

The non-covalent BTK inhibitor pirtobrutinib demonstrates efficacy in mantle cell lymphoma patients who have progressed on prior covalent BTKi therapy, overcoming a common resistance mechanism.

A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.

A steroid-sparing regimen of doxycycline, cetirizine, and valacyclovir successfully managed exaggerated mosquito bite reactions in an indolent MCL patient, offering a novel approach for this rare cutaneous manifestation.